• / Free eNewsletters & Magazine
  • / My Account
Home>Stocks>Onyx Acceptance

Onyx Acceptance

  1. All
  2. Morningstar Articles
  3. Videos
  4. 3rd Party
  5. Investing
  1. Phase 3 Head-to-Head ENDEAVOR Study Demonstrates Superiority Of Kyprolis® (carfilzomib) Over Velcade® (bortezomib) In Patients With Relapsed Multiple Myeloma

    Phase 3 Head-to-Head ENDEAVOR Study Demonstrates Superiority Of Kyprolis® (carfilzomib) Over Velcade® (bortezomib) In Patients With Relapsed Multiple Myeloma

  2. Bayer Suspends Enrollment for Phase III Trial of Regorafenib for Colorectal Cancer

    Bayer Suspends Enrollment for Phase III Trial of Regorafenib for Colorectal Cancer

  3. ClearBridge Fund Prepared for Extended Rally

    The broad stock runup in the first half of 2013 was a boon to ClearBridge Aggressive Growth, and comanager Evan Bauman says that the fund is well-positioned for the market going forward.

  4. Our Outlook for Health-Care Stocks

    Health-care stocks are on a tear as demand slowly returns.

  5. Our Outlook for the Credit Markets

    Rising interest rates have taken their toll, but as the Fed delays dialing back on stimulus, investors are poised to recapture some of their losses.

  6. Our Outlook for Health-Care Stocks

    With two years of stellar returns behind us, our expectations for 2013 are more muted, but some opportunities persist.

  7. Does This ETF Exceed the Sum of Its Parts?

    We look at how a biotech ETF holds up in an iffy climate for those stocks.

  8. Biotech Investing for the Long Haul

    Three ways to separate long-term winners from stocks that fizzle.

Upcoming Events
Conferences
Webinars

©2014 Morningstar Advisor. All right reserved.